HCA
HCA Healthcare
$376.99
▲ 0.5%Updated Today 7:15 PM ET
▼ Down 0.4% over the last 12 months
Market Cap
$83.23B
P/E
12.25x
Forward P/E (est.)
9.48x
ROE
695.7%
Revenue Growth
6.7%
EPS Growth
29.2%
Profit Margin
8.9%
FCF Yield
8.9%
Debt / Equity
54.2x
ROIC
—
Interest Coverage
—
Current Ratio
0.83x
Dividend Yield
0.8%
Implied Growth (rev. DCF)
-0.2%
Rating Score
61/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what HCA's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. HCA trades near $376.99, below its 50-day average ($421.47) and 200-day average ($460.57). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 48 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. HCA's is $11.51 (~3.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month HCA found buyers near $356.89 (support) and sellers near $401.66 (resistance); its 52-week range is $330.00–$556.52. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.5× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
HCA Healthcare (HCA) is a large-cap company in the Health Care Facilities industry, part of the Health Care sector of the S&P 500, with a market value around $83.23B.
In its latest reported year it generated about $75.60B in revenue and $6.78B in net profit.
Our model rates HCA Favorable (61/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
6.5%
Revenue moved from $58.75B in 2021 to $75.60B in 2025, a 6.5% compound annual growth rate. The most recent year grew a steady 6.7% year over year. Slower, mature growth is common for established businesses.
Gross Margin
85.0%
Operating Margin
15.7%
Net Margin
9.0%
ROE
695.7%
HCA Healthcare keeps about 8.9% of each sales dollar as net profit, with a 85.0% gross margin and 15.7% operating margin. Return on equity is 695.7%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$44.37B
Net Debt
$43.43B
Net Debt / EBITDA
—
Debt / Equity
54.2x
Leverage: debt-to-equity is 54.2x, with a current ratio of 0.8x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $44.37B of total debt against $940.00M of cash.
Operating CF
$12.64B
Free Cash Flow
$7.69B
FCF Margin
10.2%
In the latest year HCA Healthcare produced about $12.64B of operating cash flow and $7.69B of free cash flow after capital spending. That is a free-cash-flow yield of about 8.9% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
12.25x
P/S
1.16x
P/B
91.96x
EV / EBITDA
—
HCA trades at 12.3x trailing earnings (about 9.5x on estimated forward earnings), 1.2x sales, and 92.0x book value. Reverse-engineering today's price implies the market expects roughly -0.2% long-term free-cash-flow growth. That is an undemanding multiple — potentially cheap if the business is stable.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How HCA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), HCA ranks #17 of 59 by our overall rating. It trades at a discount versus the sector on earnings (12.3x P/E vs. 25.4x median) with a higher return on equity (695.7% vs. 14.9%) and slower revenue growth (6.7% vs. 7.9%).
P/E vs sector
12.3x
median 25.4x
ROE vs sector
695.7%
median 14.9%
Growth vs sector
6.7%
median 7.9%
Sector rank
#17
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$301.12 – $516.21
vs. $376.99 today · expected CAGR -4% – 6%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $80.89B | $86.55B | $92.61B | $99.10B | $106.03B |
| Net income | $7.28B | $7.79B | $8.34B | $8.92B | $9.54B |
| EPS | $32.82 | $35.11 | $37.57 | $40.20 | $43.02 |
| Share price (low) | $229.72 | $245.80 | $263.01 | $281.42 | $301.12 |
| Share price (high) | $393.81 | $421.38 | $450.88 | $482.44 | $516.21 |
| CAGR (low–high) | -39% / 4% | -19% / 6% | -11% / 6% | -7% / 6% | -4% / 6% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for HCA:
- Strong return on equity (695.7%) shows capital is put to work well.
- Healthy free-cash-flow yield (~8.9%) funds buybacks and dividends.
- Our model's overall read is Favorable (61/100).
The case against HCA:
- Elevated leverage (debt/equity 54.2x) adds financial risk.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 54.2x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: HCA Healthcare is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 12.3x earnings, which our model scores Favorable (61/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.